KEYNOTE-905: MIBC Trials and Next-Gen Medicine
Here’s a breakdown of the key takeaways from the interview, focusing on the new treatment regimen and its place in managing Muscle-invasive Bladder Cancer (MIBC):
* The Regimen: Enfortumab vedotin plus pembrolizumab is a “powerful regimen” showing critically important benefits in MIBC patients. It reduced the risk of disease progression or death by 60%.
* Patient Population: This regimen is specifically for patients ineligible for cisplatin chemotherapy. It’s crucial not to extrapolate thes results to patients who can receive cisplatin until the results of the EV-304 trial (NCT04700124) are available.
* Treatment Algorithm: For cisplatin-ineligible patients, this combination shoudl be considered a standard of care.
* Future Directions: The success of this regimen opens the door for trials aiming to avoid radical cystectomy (bladder removal) altogether, perhaps curing patients without such invasive surgery.The goal is to find ways to cure patients without removing the bladder.
* No Impact on Surgical Timing: the regimen did not worsen surgical complications and did not delay patients from undergoing necessary surgery.
In essence, this new combination therapy offers a significant advancement for a specific subset of MIBC patients, and research is ongoing to expand its applicability and potentially revolutionize treatment approaches for all MIBC patients.